Syncona Limited Nightstar closes public offering (7671C)
October 03 2018 - 1:00AM
UK Regulatory
TIDMSYNC
RNS Number : 7671C
Syncona Limited
03 October 2018
Syncona Limited
Nightstar closes public offering
03 October 2018
Syncona Ltd, a leading healthcare company focused on investing
in and building global leaders in life science, notes that its
portfolio company Nightstar Therapeutics plc ("Nightstar"), a
clinical-stage gene therapy company developing treatments for rare
inherited retinal diseases, has announced the closing of its
underwritten public offering of 4,600,000 American Depositary
Shares ("ADSs") representing 4,600,000 ordinary shares, at a public
offering price of $18.00 per ADS, which includes the exercise in
full by the underwriters of their option to purchase up to an
additional 600,000 ADSs. All ADSs sold in the offering were offered
by Nightstar.
Syncona agreed to invest $18 million (GBP13.7 million) in the
offering. Following the offering, Syncona retains a stake of 38.3%
in Nightstar (amounting to 13,203,922 ordinary shares), which was
valued at GBP185.6 million at the close of business on 02 October
2018.[1]
The offering was made only by means of a prospectus. Copies of
the final prospectus may be obtained from Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail:
Prospectus_Department@Jefferies.com; or Barclays Capital Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, telephone: (888) 603-5847, e-mail:
barclaysprospectus@broadridge.com; or UBS Securities LLC,
Attention: Prospectus Department, 1285 Avenue of the Americas, New
York, NY 10019, telephone: (888) 827-7275, email:
olprospectusrequest@ubs.com.
A registration statement relating to these securities has been
filed with, and declared effective by, the U.S. Securities and
Exchange Commission. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state or other
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay
Tel: +44 (0) 20 7611 2010
Tulchan Communications
Martin Robinson
Lisa Jarrett-Kerr
Tel: +44 (0) 207 353 4200
Forward-looking statements - this announcement contains certain
forward-looking statements with respect to the portfolio of
investments of Syncona Ltd. These statements and forecasts involve
risk and uncertainty because they relate to events and depend upon
circumstances that may or may not occur in the future. There are a
number of factors that could cause actual results or developments
to differ materially from those expressed or implied by these
forward-looking statements and forecasts. Nothing in this
announcement should be construed as a profit forecast.
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on
investing in and building global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital,
and are established leaders in gene and cell therapy. We focus on
delivering dramatic efficacy for patients in areas of high unmet
need.
About Nightstar
Nightstar is a leading clinical-stage gene therapy company
focused on developing and commercializing novel one-time treatments
for patients suffering from rare inherited retinal diseases that
would otherwise progress to blindness.
[1] As at exchange rates on 02 October 2018
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
PFUUGGACUUPRPUP
(END) Dow Jones Newswires
October 03, 2018 02:00 ET (06:00 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2024 to May 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From May 2023 to May 2024